Transcode Therapeutics Financial Leverage

Financial Leverage (Equity Multiplier) of Transcode Therapeutics is -3.61 in 2026.

Financial Leverage (Equity Multiplier) of Transcode Therapeutics changed from 3.15 to -3.61, representing a -214.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Transcode Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Transcode Therapeutics with sector peers and the industry average to assess whether it is attractive.